J Cancer 2011; 2:329-330. doi:10.7150/jca.2.329

Short Report

A Clinical Study of a Cell-Based MAGE-A3 Active Immunotherapy in Advanced Melanoma Patients

Vincenzo Russo1, Francesca Lunghi2, Raffaella Fontana1, Marco Bregni3 ✉

1. Cancer Gene Therapy Unit, San Raffaele Scientific Institute, via Olgettina 60, 20132, Milan, Italy;
2. Bone Marrow Transplantation Unit, San Raffaele Scientific Institute, via Olgettina 60, 20132, Milan, Italy;
3. Strategic Program in Oncology, San Raffaele Scientific Institute, via Olgettina 60, 20132, Milan, Italy.

Abstract

In this bi-institutional study, twenty-three stage IIIC-IV MAGE-A3+ melanoma patients were vaccinated with M3TK-GML biweekly at three dose levels, with a subsequent phase of vaccinations at the maximum dose level. Anti-MAGE-A3 and anti-TK T cells were assessed by in vitro assay and delayed-type hypersensitivity skin testing.

Keywords: MAGE-A3, Melanoma, Immunotherapy

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
How to cite this article:
Russo V, Lunghi F, Fontana R, Bregni M. A Clinical Study of a Cell-Based MAGE-A3 Active Immunotherapy in Advanced Melanoma Patients. J Cancer 2011; 2:329-330. doi:10.7150/jca.2.329. Available from http://www.jcancer.org/v02p0329.htm